OpenAI says EU ‘OpenAI tokens’ are not OpenAI equity and were not approved by the company

OpenAI’s official statement

OpenAI published a formal notice on February 14, 2026 addressing Robinhood’s launch of EU products labeled as ‘OpenAI tokens.’ The company stated that these instruments are not OpenAI equity and were not created through any authorized partnership with OpenAI. The clarification was direct and categorical, aimed at preventing users from interpreting branded token products as equivalent to ownership rights in the private company.

OpenAI also reiterated a governance rule that is central to private-share transactions: any transfer of OpenAI equity requires prior approval from OpenAI. In the same notice, the company said it had not approved any transfer associated with the products in question. This distinction matters because token wrappers, synthetic exposure products, and branding language can look similar to retail users while representing very different legal claims.

Why this matters beyond one product

The incident sits at the intersection of AI market hype and tokenized finance. As demand for pre-IPO exposure grows, platforms have incentives to package private-company narratives into tradable formats. But investor understanding often lags structure complexity. OpenAI’s notice highlights that issuer name recognition does not establish equity rights, voting rights, or transfer legitimacy.

For market operators, this is a compliance and disclosure stress test. If tokenized products reference private companies without clear legal mapping, confusion risk increases quickly, especially in cross-border retail contexts. OpenAI’s language effectively draws a bright line between reference exposure and actual capitalization table ownership, a line regulators may increasingly require platforms to make explicit.

What to watch next

OpenAI said it is continuing to investigate the situation and advised users to rely on official communications. Near term, key signals will include whether product disclosures are revised and how EU market supervisors interpret naming, representation, and suitability obligations for tokenized instruments tied to private issuers. Longer term, the case may accelerate standardized disclosure frameworks for tokenized private-equity exposure.